We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Use of Niclosamide to Deactivate Cancer Stem Cells

By LabMedica International staff writers
Posted on 06 Dec 2017
Nanoparticles designed to selectively deliver the drug niclosamide to cancer stem cells caused the cancer stem cells to lose their stem-like properties and rendered them less able to cause recurrence or metastasis.

Cancer stem cells are known to be controlled by pathways that are dormant in normal adult cells. More...
An example is PTEN, which is a negative regulator of the transcription factor STAT3. STAT3 regulates genes that are involved in stem cell self-renewal and thus represents a novel therapeutic target.

In order to manipulate STAT3 expression, investigators at the University of Illinois (Champaign-Urbana, USA) synthesized nanoparticles from a biocompatible polymer and coated them with antibodies directed at the CD44 protein, which only appears on the surface of cancer stem cells. The nanoparticles were loaded with the widely used anti-parasite drug niclosamide, which deactivates the STAT3 pathway.

Results published in the November 14, 2017, online edition of the journal Molecular Cancer Therapeutics revealed that treatment with the nanoparticles caused cancer stem cells in culture to lose their stem like properties, making them less able to cause the cancer to recur or metastasize. In addition, there was a significant decrease in overall cancer cell growth, both in the cell cultures and in mice.

"I call them "GPS-enabled nanoparticles," because they seek out only the cells that have cancer stem cell properties. Then they latch onto the cells and deliver the drug," said senior author Dr. Dipanjan Pan, professor of bioengineering at the University of Illinois. "To the best of our knowledge, this is the first demonstration of delivering cancer stem-cell-targeted therapy with a nanoparticle. We purposely used an extremely inexpensive drug. It is generic and we can mass produce it on a very large scale. The nanoparticles are a polymer that we can make on a large scale – it is highly defined and consistent, so we know exactly what we are delivering. The rest of the process is just self-assembly."

"It is critical to administer treatments for already-developed tumors; however, long-term survival and not allowing it to come back are equally important," said Dr. Pan. "We want to destroy the cells that are hidden in the tissue and cause the cancer to come back or spread to other parts of the body."

Related Links:
University of Illinois


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.